Participants
psychiatric, cardiovascular disease, inflammatory bowel disease
DISEASE, TYPE 1 DIABETES, GASTROPARESIS, PANCREATITIS
Participants were screened between September 14, 2018, and October 29, 2019, and commenced treatment between October 24, 2018, and November 28, 2019. Key exclusion criteria were type 1 diabetes; severe psychiatric disease; severe kidney, liver, or cardiovascular disease; inflammatory bowel disease, history of pancreatitis; gastroparesis; concomitant use of dipeptidyl peptidase IV–inhibitors, GLP-1–receptor agonists, insulin, or other medications that affect weight; pregnancy; and breastfeeding. Full eligibility criteria are in the study protocol in 